ArticleFrontiers in genetics2021
Epigenetic Age Acceleration of Stomach Adenocarcinoma Associated With Tumor Stemness Features, Immunoactivation, and Favorable Prognosis.
Article in Frontiers in genetics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 16 citations in OpenAlex.
- Abnormal epigenetic aging of epigenetic outliers in normal colon mucosa from colorectal cancer patients.Scientific reports · 2026Article
- The Role of DNA Methylation in Gastrointestinal Disease: An Expanded Review of Malignant and Nonmalignant Gastrointestinal Diseases.Gastroenterology · 2025Review
- Normal gastric tissueEpigenetics reports · 2025Article
- Development and pan-cancer validation of an epigenetics-based random survival forest model for prognosis prediction and drug response in OS.Frontiers in pharmacology · 2025Article
- ImAge quantitates aging and rejuvenation.Nature aging · 2024Article
- Unveiling the role of RARs in stomach adenocarcinoma: clinical implications and prognostic biomarkers.Translational cancer research · 2024Article
- DNA methylation drives a new path in gastric cancer early detection: Current impact and prospects.Genes & diseases · 2024Review
- Imaging-based chromatin and epigenetic age, ImAge, quantitates aging and rejuvenation.Research square · 2023Article
- Cytokine-Like Protein 1 (CYTL1) as a Key Target of M-Stage Immune Infiltration in Stomach Adenocarcinoma.BioMed research international · 2023Article
- Development of a prognostic metabolic signature in stomach adenocarcinoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022Article
- Identification of 8-gene risk prediction signature associated withJournal of gastrointestinal oncology · 2022Article
- Identification of circRNA-miRNA-Immune-Related mRNA Regulatory Network in Gastric Cancer.Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.